The opioid crisis is making its way into the “S” and “G” of ESG-focused investments.
A growing number of institutional investors are pursuing policy changes at drugmakers and distributors to help mitigate the crisis, with some success.
Using shareholder resolutions and direct communications with corporate executives, they are pushing for better oversight of financial and reputational risks related to the opioid crisis.
